Revolution Medicines registers Phase 3 RASolute 309 in KRAS G12D pancreatic cancerSep 8Trial updatedaraxonrasibRevolution Medicines, Inc.
Incyte-backed trials: OSU tests pemigatinib cycling regimen; OHSU starts Opzelura pilot for PGAug 24Weekly roundup, 2 itemsIncyte Corporationpemigatinib
AbbVie posts results from terminated emraclidine trial, opens two studies to recruitmentAug 21Weekly roundup, 4 itemsAbbVieemraclidine
Can-Fite reports preclinical data on namodenoson-gemcitabine combination in pancreatic cancerAug 17Clinical readoutCan-Fite BioPharmagemcitabine
Incyte-linked filings this week: FIGHT-302 results posted, new academic pancreatic trial listedAug 14Weekly roundup, 2 itemsIncyte Corporationpemigatinib
RenovoRx completes Phase III enrollment, raises 2026 revenue guidanceAug 13Quarterly updateRenovoRx, Inc
Acrivon reports Q2 2026 results, flags ACR-368 interim data for second half of 2026Aug 12Quarterly updateACR-2316Acrivon Therapeutics
Theriva doses first patients in VIRAGE2 trial of VCN-01 in pancreatic cancerAug 11Quarterly updateTheriva Biologics, Inc.
Theriva doses first patient in VIRAGE2 trial testing repeat VCN-01 dosing in pancreatic cancerAug 6Clinical readoutTheriva Biologics, Inc.
Ocrevus higher-dose Phase 3 posts results, misses primary endpoint; two partner trials updateJul 24Weekly roundup, 4 itemsobinutuzumabocrelizumab
Molecular Partners reports progress in Phase 2 TACTIC trial of MP0317 for cholangiocarcinomaJul 20Clinical readoutMolecular Partners AG
BMS trials post results across lung cancer, sarcoma, myelofibrosis; new stroke study opensJul 17Weekly roundup, 5 itemsBristol Myers Squibblisocabtagene maraleucel
Theriva gets Spanish authorization for VIRAGE2 trial of VCN-01 in pancreatic cancerJul 7Clinical readoutTheriva Biologics, Inc.
Sanofi posts pediatric Hectorol results; USC germ cell trial data also reportedJul 2Weekly roundup, 4 itemsdoxercalciferolSanofi
Sign inSign in